CLLS - Cellectis Biotherapeutics Company Total Debt

The market dynamics of Cellectis S.A. (CLLS) allow for an assessment of the company's debt load, which currently stands at 0.11. The business relies on the high-tech UCEL complex, where capacities are being expanded and bioreactor sterility is strictly monitored. A team of outstanding geneticists, with access to cutting-edge laboratories and full creative independence in the fight against cancer, ensures the success of these projects.

Cellectis - CLLS Company Debts (period 07/04/2022 - 10/27/2026)

Financial and market metric breakdowns for Cellectis S.A. (CLLS)

- price and consensus price forecast:

Share Price cellectis.com|CLLS - Analyst Consensus Forecast

- market capitalization data:

Market Valuation Cellectis Biotherapeutics|CLLS - Total Company Value

- book capitalization data:

Net Asset Value per Share Cellectis S.A.|CLLS - Company Book Value|Market Value to Book Value Ratio cellectis.com|CLLS - Aggregate Company Assets

- debt and liquidity data:

Debt to Capital Cellectis S.A.|CLLS - Long-Term Debt to Capital|Short-Term Indebtedness to Equity cellectis.com|CLLS - Company Total Debt|Debts to Book Value Cellectis Biotherapeutics

Fundamental company valuation:CLLS (Cellectis SA)

This indicator reflects the real-time dynamics of the issuer's total credit obligations. By analyzing the total amount of borrowings, an investor assesses the business's degree of financial autonomy. The metric captures the balance between raising capital and the risk of liquidity loss. For Cellectis S.A. (CLLS), a low debt load is critical when receiving licensing payments from oncology centers. This ensures the stable development of genome editing technologies without excessive pressure from creditors.

Main competitors